Brief: Cullinan Therapeutics Receives Approval From European Medicines Agency To Initiate Phase 1 Trial Of Cln-978
16/04/2025 12:17
April 16 (Reuters) - Cullinan Therapeutics Inc CGEM.O: CULLINAN THERAPEUTICS RECEIVES APPROVAL FROM EUROPEAN MEDICINES AGENCY TO INITIATE PHASE 1 TRIAL OF CLN-978, A BISPECIFIC CD19 T CELL ENGAGER ADMINISTERED SUBCUTANEOUSLY, IN PATIENTS WITH RHEUMATOID ARTHRITIS Source text: ID:nGNX3v0ZnH Further company coverage: CGEM.O ((Reuters.Briefs@thomsonreuters.com;))